Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellular radiosensitivity and complication risk after curative radiotherapy.

J Peacock1, A Ashton, J Bliss

  • 1Section of Radiotherapy and Section of Epidemiology, Institute of Cancer Research, 15 Cotswold Road, Sutton, UK.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|May 9, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial.

ESMO gastrointestinal oncology·2026
Same author

ESMO Guidance for Reporting Oncology real-World evidence (GROW).

ESMO real world data and digital oncology·2026
Same author

A Scoping Review of Human Teratogens and Their Impact on the Developing Brain: A Contribution From the ConcePTION Project.

Birth defects research·2025
Same author

Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial.

ESMO open·2025
Same author

Patient Experiences of Using Wearable Health Monitors During Cancer Treatment: A Qualitative Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024

This study found no link between fibroblast radiosensitivity and radiotherapy complications in breast cancer patients. Other factors likely explain variations in normal tissue damage after treatment.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Cell Biology

Background:

  • Radiotherapy dose fractionation is a standard treatment for breast cancer.
  • Late normal tissue effects can occur years after radiotherapy.
  • Inter-patient variability in these effects suggests underlying biological differences.

Purpose of the Study:

  • To investigate the association between in vitro fibroblast radiosensitivity and the risk of radiotherapy complications.
  • To determine if cellular radiosensitivity predicts normal tissue damage in breast cancer patients.

Main Methods:

  • A case-control study of breast cancer patients from a radiotherapy dose fractionation trial.
  • Fibroblast cell survival assays were performed at high and low dose rates.
  • Patients were selected based on the presence (cases) or absence (controls) of late normal tissue changes.

Related Experiment Videos

Main Results:

  • Significant inter-patient variation in fibroblast radiosensitivity was observed.
  • No association was found between fibroblast radiosensitivity and the development of late radiotherapy normal tissue effects.
  • This suggests cellular radiosensitivity is not a primary determinant of complication risk.

Conclusions:

  • Inter-individual variation in cellular radiosensitivity may not be the main factor determining radiotherapy complication risk in breast cancer.
  • Other biological and technical factors are likely more important in explaining differences in normal tissue damage.
  • Further research is needed to identify key determinants of radiotherapy-induced normal tissue injury.